<DOC>
	<DOCNO>NCT02576548</DOCNO>
	<brief_summary>This research study design evaluate experimental drug , MEDI4276 , treat breast stomach ( gastric ) cancer .</brief_summary>
	<brief_title>A Phase 1/2 Study MEDI4276 Adults Subjects With Select HER2-expressing Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Histologically cytologically document unresectable , locally advanced metastatic breast cancer gastric cancer refractory standard therapy . 1 . For subject breast cancer : Prior treatment trastuzumab , pertuzumab , TDM1 , either alone combination , require . Subjects primary tumor hormone ( estrogen , progesterone , ) receptorpositive receptornegative eligible . Prior hormone therapy allow , last dose must least 14 day prior first dose MEDI4276 . 2 . For subject gastric cancer : Prior treatment trastuzumab contain chemotherapy regimen require . 3 . HER2 Positive disease document FISHpositive and/or 3+ IHC previously collect tumor tissue . 4 . At least one lesion measurable RECIST Version 1.1 . 1 . Receipt conventional investigational anticancer treatment within 28 day prior first dose MEDI4276 . 2 . History exposure follow cumulative dos anthracyclines : 1 . Doxorubicin liposomal doxorubicin &gt; 350 mg/m² . 2 . Epirubicin &gt; 530 mg/m² . 3 . Mitoxantrone &gt; 90 mg/m² idarubicin &gt; 70 mg/m² . 4 . If another anthracycline 1 anthracycline use , cumulative dose must exceed equivalent 350 mg/m² doxorubicin . 3 . Known brain metastasis untreated , symptomatic , require therapy control symptom ; radiation , surgery therapy control symptom brain metastasis within 2 month prior first dose MEDI4276 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>